First, we found that TOX, but not PD-1, was an ideal indicator of HBV-induced HCC, and PD-1 was insufficiently sensitive to this type of HCC, which explained why it did not gain sufficient benefit from anti-PD-1 antibody to some extent (5). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.